BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22285696)

  • 1. Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice.
    Boross P; Jansen JH; Pastula A; van der Poel CE; Leusen JH
    Immunol Lett; 2012 Mar; 143(1):44-52. PubMed ID: 22285696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
    Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
    J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.
    Beum PV; Mack DA; Pawluczkowycz AW; Lindorfer MA; Taylor RP
    J Immunol; 2008 Dec; 181(11):8120-32. PubMed ID: 19018005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of interleukin-6 production by rituximab in human B cells.
    Jones JD; Hamilton BJ; Skopelja S; Rigby WF
    Arthritis Rheumatol; 2014 Nov; 66(11):2938-46. PubMed ID: 25080282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments.
    Taylor RP; Lindorfer MA
    Blood; 2015 Jan; 125(5):762-6. PubMed ID: 25498911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.
    Vaughan AT; Chan CH; Klein C; Glennie MJ; Beers SA; Cragg MS
    J Biol Chem; 2015 Feb; 290(9):5424-37. PubMed ID: 25568316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.
    Beum PV; Peek EM; Lindorfer MA; Beurskens FJ; Engelberts PJ; Parren PW; van de Winkel JG; Taylor RP
    J Immunol; 2011 Sep; 187(6):3438-47. PubMed ID: 21841127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
    Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF
    J Exp Med; 2006 Mar; 203(3):743-53. PubMed ID: 16520392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cleavage of the interchain disulfide bonds in rituximab increases its affinity for FcγRIIIA.
    Suzuki M; Yamanoi A; Machino Y; Kobayashi E; Fukuchi K; Tsukimoto M; Kojima S; Kohroki J; Akimoto K; Masuho Y
    Biochem Biophys Res Commun; 2013 Jul; 436(3):519-24. PubMed ID: 23764395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
    Rossi EA; Chang CH; Goldenberg DM
    PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.
    Lim SH; Vaughan AT; Ashton-Key M; Williams EL; Dixon SV; Chan HT; Beers SA; French RR; Cox KL; Davies AJ; Potter KN; Mockridge CI; Oscier DG; Johnson PW; Cragg MS; Glennie MJ
    Blood; 2011 Sep; 118(9):2530-40. PubMed ID: 21768293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of Trogocytosis: Quantitative Analyses Validated with Rigorous Controls.
    Taylor RP; Lindorfer MA
    Curr Protoc; 2023 Oct; 3(10):e897. PubMed ID: 37830752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.
    Xiu Y; Wong CP; Bouaziz JD; Hamaguchi Y; Wang Y; Pop SM; Tisch RM; Tedder TF
    J Immunol; 2008 Mar; 180(5):2863-75. PubMed ID: 18292508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
    Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
    J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.
    Bowles JA; Wang SY; Link BK; Allan B; Beuerlein G; Campbell MA; Marquis D; Ondek B; Wooldridge JE; Smith BJ; Breitmeyer JB; Weiner GJ
    Blood; 2006 Oct; 108(8):2648-54. PubMed ID: 16825493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
    J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.
    Beers SA; French RR; Chan HT; Lim SH; Jarrett TC; Vidal RM; Wijayaweera SS; Dixon SV; Kim H; Cox KL; Kerr JP; Johnston DA; Johnson PW; Verbeek JS; Glennie MJ; Cragg MS
    Blood; 2010 Jun; 115(25):5191-201. PubMed ID: 20223920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
    Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
    J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma.
    Lara S; Heilig J; Virtanen A; Kleinau S
    BMC Cancer; 2022 Jun; 22(1):678. PubMed ID: 35725455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
    Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
    MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.